Skip to main content
Clinical Trials/NCT05756452
NCT05756452
Recruiting
Not Applicable

Linking Cardiac Autonomic Dysfunction and InfLammation in Patients With Acute Coronary Syndromes: a Complex Puzzle to be Solved With Potential Therapeutic Implications (CADILACS Study)

Fondazione Policlinico Universitario Agostino Gemelli IRCCS1 site in 1 country90 target enrollmentFebruary 17, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Acute Coronary Syndrome
Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Enrollment
90
Locations
1
Primary Endpoint
The correlation between HRV and CRP parameters in ACS patients with obstructive CAD
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

Subclinical inflammation plays a critical role in all stages of the atherosclerotic process, from the initiation of the fatty streaks to the development of plaque instability and rupture, causing myocardial ischemia and acute coronary syndromes (ACS).

A few studies have suggested that the autonomic nervous system (ANS) and the inflammatory response are intimately linked. Accordingly, a relation between impaired cardiac autonomic tone and increased markers of inflammation has been reported in healthy subjects as well as in patients with type 1 diabetes mellitus, chronic coronary syndrome or decompensated heart failure.

To get insight in the controversial relationship between cardiac autonomic dysfunction and inflammation in patients with ACS both with and without obstructive CAD and assess the precise mechanisms and molecular pathways by which these two pathophysiological conditions mutually influence each other, to characterize their prognostic implications and identify possible targets for novel therapeutic strategies.

Detailed Description

A comprehensive assessment of cardiac autonomic function and inflammatory profile will be performed in ACS patients with obstructive CAD (n=45) or with NO-CAD (n=45) at coronary angiography. In the sub-acute phase (1 to 6 months after the ACS) all patients will undergo a global echocardiographic evaluation, a 24-hour ECG Holter recording to assess HRV and blood samples collection for neurotransmitter measurements, platelet activation and reactivity evaluation and inflammatory profile assessment by proteomics analysis, inflammasome activity evaluation, NLRP3, pro-IL-18 and pro-IL-1β expression level by qPCR and epigenetic analysis. A follow-up to establish clinical conditions of patients will be done after 12 months by direct clinical visit, trans-thoracic echocardiogram to evaluate cardiac remodeling, HRV assessment by 24-hour ECG Holter recording and blood sample collection to evaluate the inflammatory profile as it was assessed at baseline.

Registry
clinicaltrials.gov
Start Date
February 17, 2023
End Date
February 1, 2025
Last Updated
3 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Lanza Gaetano Antonio

Principal Investigator

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Eligibility Criteria

Inclusion Criteria

  • Age ≥18 years;
  • Evidence of previous complete percutaneous revascularization;
  • ACS, with or without CAD, experienced in the previous 3 months ±15 days;
  • Signed written informed consent.

Exclusion Criteria

  • History of previous acute myocardial infarction (AMI);
  • Prior surgical myocardial revascularization via coronary artery bypass graft (CABG);
  • Previous incomplete percutaneous myocardial revascularization, as indicated by documentation of residual stenosis \>50% or FFR ≤0.8 in any epicardial vessel;
  • Killip class III-IV in admission;
  • Established cardiovascular disease (assessed by clinical evaluation, physical exam, 12-lead ECG, or transthoracic echocardiogram), such as congenital heart disease, cardiomyopathy, and severe valvular heart disease;
  • Serious medical conditions, including severe renal insufficiency (eGFR \> 30 ml/min), hepatic insufficiency or cirrhosis, malignancies, COPD (GOLD stage III-IV), and acute or chronic inflammatory diseases;
  • Refusal to sign the written informed consent to participate in the study.

Outcomes

Primary Outcomes

The correlation between HRV and CRP parameters in ACS patients with obstructive CAD

Time Frame: 12 months

The primary endpoint of the study is to identify a difference in the correlation between HRV and CRP parameters in ACS patients with or without obstructive CAD. This study will be performed through a detailed history and clinical evaluation based on transthoracic Doppler echocardiography (TTDE) and 24-hour Holter ECG recording.

The correlation between HRV and CRP parameters in ACS patients without obstructive CAD

Time Frame: 12 months

The study is important to identify the differences between HRV and CRP parameters ACS patients without obtructive CAD. It is important to group several exams: sample blood, transthoracic Doppler echocardiography (TTDE) and 24-hour Holter ECG recording.

Secondary Outcomes

  • Evaluate cardiac autonomic dysfunction associated to a systemic inflammation(12 months)

Study Sites (1)

Loading locations...

Similar Trials